| abstract |
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen nreceptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which ncontain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis nProteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the nrespective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the ntarget protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target nprotein. The present disclosure exhibits a broad range of pharmacological activities associated with ndegradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation nof the target protein are treated or prevented with compounds and compositions of the present disclosure. |